India is ranked 12th in the world in biotech and third in Asia-Pacific.

Biotechnology Industry in India

Latest update: July, 2015

Exponential growth in government funding     


• Government spending on healthcare, as a percentage of GDP, for the 12th Five-Year Plan is around 2.5 per cent 

• Government expenditure on healthcare as a percentage of total expenditure on healthcare in the country was 31 per cent in 2013 

• During the 11th Five-Year Plan, the Department of Biotechnology utilised 95 per cent of the allocated resources 

Exponential growth in government funding

12th  Five year plan fund allocation


• The overall strategy of 12th Five-Year Plan is to aaccelerate the pace of research, innovation and development. 

• The government plans to strengthen regulatory science and infrastructure, which involves setting up the Biotechnology Regulatory Authority of India (BRAI) and a central agency for regulatory testing and certification of laboratories 

• The plan also entails expanding and commissioning new bioclusters at Faridabad, Mohali Kalyani and Hyderabad 

Funds allocated for biotechnology under 12th Five Year Plan

Updated: July, 2015



The Biotech industry in India has been able to successfully position itself to capitalise on the unfolding global biologics opportunity by attracting talent with advanced technical skill-sets.

The biotechnology sector of India is highly innovative and is on a high growth trajectory. The sector, with its immense growth potential, will continue to play a more significant role as an innovative manufacturing hub. The sector is one of the most significant sectors in enhancing India's global profile as well as contributing to the growth of the economy. This sector is directly or indirectly related to the health as well as the agricultural sector of India.

India is among the top 12 biotech destinations in the world and is the largest producer of recombinant Hepatitis B vaccine. Out of the top 10 biotech companies in India (by revenue), six focus their expertise in bio-pharmaceuticals and four specialise in agri-biotech.

India had recently overtaken Canada to emerge as the fourth largest country to grow biotech or genetically modified (GM) crops, as farmers here planted Bt cotton in about 11 million hectares. The global acreages under GM crops increased to 175.2 million hectares in 2013, about five million hectares more than the previous year.

India also has no dearth of talent in this sector, as a number of institutions, both government and autonomous, provide the necessary opportunities for the student seeking to obtain a degree in this sector. Also, the Government of India has provided adequate scope to this sector by providing facilities for research and development (R&D) in the field of biotechnology.

Market size

The Indian biotech industry holds about 2 per cent share of the global biotech industry.

The Indian biotechnology sector is expected to grow from the current US$ 5-7 billion to US$ 100 billion by 2025 by doubling the growth rate of this sector from 15 percent to 30 percent, according to the Association of Biotechnology Led Enterprises (ABLE).

The high demand for different biotech products has also opened up scope for the foreign companies to set up bases and reap great profits. The biotechnology industry in India, comprising about 400 companies, has grown three-fold in the last five years to reach US$ 4 billion in FY 13. Growing at an average rate of about 20 per cent, India's biotech industry comprising biopharmaceuticals, bioservices, bioagriculture, bioindustry and bioinformatics could reach the US$ 7 billion mark by FY 15.

Biopharma is the largest sector contributing about 62 per cent of the total revenue followed by bioservices (18 per cent), bioagri (15 per cent), bioindustry (four per cent), and bioinformatics contributing (one per cent).

India has emerged as a leading destination for clinical trials, contract research and manufacturing activities owing to the growth in the bioservices sector, which accounts for revenue generation worth about US$ 636.73 million.


India's biotech sector has attracted significant amount of attention over the past two decades. Several global companies have aggressively joined hands with Indian companies due to India's strong generic biotechnology potential. Some of the recent investments in this sector are as follows:

  • Shantha Biotechnics Pvt. Ltd has started building a facility to manufacture Insuman, an insulin product to treat diabetes. French pharmaceutical company Sanofi SA, which acquired Shantha Biotechnics in 2009 through its vaccines division, Sanofi Pasteur SA, is investing Rs 460 crore (US$ 73.59 million) to build the facility that, at full capacity, will produce 60 million Insuman cartridges annually, company executives said.
  • Hyderabad headquartered vaccine manufacturer Indian Immunologicals Ltd ( IIL), part of the National Dairy Development Board, is setting up a new vaccine manufacturing facility in Pondicherry involving an investment of Rs 300 crore (US$ 47.99 million). This is the fourth facility for Indian Immunologicals, which currently has two facilities in Hyderabad and one in Ooty.
  • In a significant development for Kerala-based Arjuna Natural Extracts Ltd, the company has received a patent in the United States on BCM-95, a turmeric extract formulation that could be used to target Alzheimer’s disease. Explaining the application patent, Mr Benny Antony, Joint Managing Director of the company said, the product is a re-blend of two ingredients in turmeric, but in a ratio that is not seen in naturally occurring turmeric. It is a reblend of curcuminoid and an essential oil of turmeric, he said.
  • Bristol-Myers Squibb and Syngene International, the contract research subsidiary of Biocon, have announced a five-year extension of their drug discovery and development collaboration in India.
  • The Bhabha Atomic Research Centre (BARC) through its Centre for Incubation of Technologies (BARCIT) has signed a memorandum of understanding (MoU) with M/s Veena Industries, Nagpur, for incubation of technology for biodegradable and edible films for food and pharmaceuticals packaging.
  • Cancer Genetics Inc (CGI) has acquired Hyderabad-based genomics services provider BioServe India for US$ 1.9 million. This will enable CGI to better position themselves globally in personalised cancer care.

Government Initiatives

A Network of Technology Centres and promotion of start-ups by SIDBI are among few of the steps taken by the government to promote innovation and entrepreneurship in agro industry proposed by the MSME Ministry in a new scheme. The scheme follows the announcement of a Rs 200 crore (US$ 31.99 million) fund by Finance Minister Mr Arun Jaitley in his Budget speech this year for promoting innovation and entrepreneurship in agro industry.

The Government of India has taken a lot of initiatives to improve the biotechnology sector in the country as well as offer enough scope for research in this field. The Department of Biotechnology (DBT) along with other government funded institutions such as National Biotechnology Board (NBTB) and many other autonomous bodies representing the biotechnology sector, are actively working together so as to project India as a global hub for biotech research and business excellence. Some of the recent major initiatives are as follows:

  • CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT) has signed an MoU with Phyto Biotech to formalise transfer of technology, for production of unique autoclavable super oxide dismutase (SOD) enzyme, used in cosmetic, food and pharmaceutical industries for end applications.
  • DBT has announced the Indo-Australian Career Boosting Gold Fellowships under which it will support the researchers to undertake a collaborative research project at a leading science institute or university in Australia for a period of up to 24 months.
  • DBT has allocated Rs 4.6 crore (US$ 735,983.05) to the University of Agricultural Sciences (UAS) to support a national multi-institutional project titled 'A value chain on jackfruit and its products'.
  • Under the 12th Five Year Plan, the Government of India plans to strengthen regulatory science and infrastructure, which involves setting up of Biotechnology Regulatory Authority of India (BRAI) and a central agency for regulatory testing and certification laboratories.

Road Ahead

With the country offering numerous comparative advantages in terms of R&D facilities, knowledge, skills, and cost effectiveness, the biotechnology industry in India has immense potential to emerge as a global key player.

India currently has a marginal share in the global market for industrial enzymes that is estimated to reach about US$ 4.4 billion by 2015. Hence, there is an opportunity in focused R&D and knowledge-based innovation in the field of industrial enzymes, which can innovatively replace polluting chemical processes into eco-friendly processes that also deliver environmental sustainability. Another interesting field of study is the area of bio-markers and companion diagnostics, which will enable to optimise the benefits of biotech drugs.

The growth in gross domestic product (GDP) over the next decade will expand the domestic market and Indians will be able to afford healthcare products, and demand for food commodities and energy will grow too. Presently, many countries are looking forward to invest in the Indian biotechnology sector.

India has all the ingredients to become a global leader in affordable healthcare. If there is an annual investment of US$ 4.01 billion to US$ 5.02 billion in the next five years, the biotech industry can grow to US$ 100 billion by 2025, with a 25 per cent return on investment, and set a growth rate of 30 per cent year-on-year.

With all the support, government initiatives and determination to excel, India can soon attain global leadership in providing affordable healthcare and innovative medicines, quality food and feed for all.

Exchange Rate Used: INR 1 = US$ 0.016 as on March 20, 2015

References: Press Information Bureau (PIB), Media Reports and Press Releases, Department of Industrial Policy and Promotion (DIPP), Department of Biotechnology.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.


Brand India Pharma


The Indian biotechnology sector is expected to clock US$ 10 billion in revenue by 2015 on the back of emerging opportunities from around the world.

+ More >

Brand India Pharma

IBEF Publications

IBEF Publication

India Now Magazine

India Now Business and Economy


+ More Publications >

IBEF Publication

Blog – Perspectives on India More

Powered by the Who's Who of India

Loading blogs ...

ideas More


This Gecko is not a lizard. It is a bluetooth low energy (BLE) device that works as an appcessory (an accessory with smartphone app), to make your smartphone even smarter.


Join now. Enjoy FREE subscriptions downloads, updates and more.


Already a member?
Login / Retrieve Password

Copyright © 2010-2015 India Brand Equity Foundation

All material, information, data, images or content on this website is subject to copyright or other applicable intellectual property laws and no part of it can be reproduced in any form (including paper or electronic form) without prior written consent and approval from IBEF. Infringements are subject to prosecution under the applicable laws. For consent related queries and conditions,
please write to

IndiaAn initiative of the Ministry of Commerce & Industry, Government of India